首页> 外文期刊>Neuropsychiatric Disease and Treatment >Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials
【24h】

Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials

机译:奥氮平/氟西汀联合治疗难治性抑郁症的疗效和安全性:一项随机对照试验的荟萃分析

获取原文
       

摘要

Background: Whether olanzapine/fluoxetine combination (OFC) is superior to olanzapine or fluoxetine monotherapy in patients with treatment-resistant depression (TRD) remains controversial. Thus, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of OFC with olanzapine or fluoxetine monotherapy for patients with TRD. Materials and methods: RCTs published in PubMed, Embase, Web of Science, and the ClinicalTrials.gov registry were systematically reviewed to assess the efficacy and safety of OFC. Outcomes included mean changes from baseline in Montgomery–Asberg Depression Rating Scale (MADRS), Clinical Global Impression-Severity (CGI-S), Hamilton Rating Scale for Anxiety (HAM-A), Brief Psychiatric Rating Scale (BPRS) scores, response rate, remission rate, and adverse events. Results were expressed with weighted mean difference (WMD) with 95% confidence intervals (CIs) and risk ratio (RR) with 95% CIs. Results: A total of five RCTs with 3,020 patients met the inclusion criteria and were included in this meta-analysis. Compared with olanzapine or fluoxetine monotherapy, OFC was associated with greater changes from baseline in MADRS (WMD?=-3.37, 95% CI: -4.76, -1.99; P <0.001), HAM-A (WMD?=-1.82, 95% CI: -2.25, -1.40; P <0.001), CGI-S (WMD?=-0.37, 95% CI:?-0.45,?-0.28; P <0.001), and BPRS scores (WMD?=-1.46, 95% CI: -2.16, -0.76; P <0.001). Moreover, OFC had significantly higher response rate (RR?=1.35, 95% CI: 1.12, 1.63; P =0.001) and remission rate (RR?=1.71, 95% CI: 1.31, 2.23; P <0.001). The incidence of treatment-related adverse events was similar between the OFC and monotherapy groups (RR?=1.01, 95% CI: 0.94, 1.08; P =0.834). Conclusion: OFC is more effective than olanzapine or fluoxetine monotherapy in the treatment of patients with TRD. Our results provided supporting evidence for the use of OFC in TRD. However, considering the limitations in this study, more large-scale, well-designed RCTs are needed to confirm these findings.
机译:背景:对于难治性抑郁症(TRD)患者,奥氮平/氟西汀组合(OFC)是否优于奥氮平或氟西汀单药治疗仍存在争议。因此,我们对随机对照试验(RCT)进行了荟萃分析,以比较OFC与奥氮平或氟西汀单药治疗TRD的疗效和安全性。材料和方法:系统评价了发表在PubMed,Embase,Web of Science和ClinicalTrials.gov注册中心的RCT,以评估OFC的疗效和安全性。结果包括蒙哥马利-阿斯伯格抑郁量表(MADRS),临床总体印象严重度(CGI-S),汉密尔顿焦虑量表(HAM-A),简明精神病量表(BPRS)得分,缓解率与基线相比的平均变化。 ,缓解率和不良事件。结果用具有95%置信区间(CIs)的加权平均差(WMD)和具有95%CI的风险比(RR)表示。结果:共有5项RCT与3,020例患者符合纳入标准,并纳入本荟萃分析。与奥氮平或氟西汀单药治疗相比,OFC与MADRS基线水平的较大变化相关(WMD?=-3.37,95%CI:-4.76,-1.99; P <0.001),HAM-A(WMD?=-1.82,95) CI百分比:-2.25,-1.40; P <0.001),CGI-S(WMD?=-0.37,95%CI:?-0.45,?-0.28; P <0.001)和BPRS得分(WMD?=-1.46) ,95%CI:-2.16,-0.76; P <0.001)。而且,OFC具有显着更高的响应率(RR≥1.35,95%CI:1.12,1.63; P = 0.001)和缓解率(RR≥1.71,95%CI:1.31,2.23; P <0.001)。 OFC组和单药组之间的治疗相关不良事件的发生率相似(RR?= 1.01,95%CI:0.94,1.08; P = 0.834)。结论:OFC比奥氮平或氟西汀单药治疗TRD更有效。我们的结果提供了在TRD中使用OFC的支持证据。但是,考虑到本研究的局限性,需要更大规模,设计良好的RCT来证实这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号